financetom
Business
financetom
/
Business
/
CCI slaps Rs 223.48-crore penalty on MakeMyTrip, Rs 168.88 crore on OYO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CCI slaps Rs 223.48-crore penalty on MakeMyTrip, Rs 168.88 crore on OYO
Oct 19, 2022 10:35 AM

The Competition Commission of India (CCI) on Wednesday, October 19, imposed penalties of Rs 223.48 crore and Rs 168.88 crore on online travel services firm Make My Trip-Goibibo (MMT-Go) and hospitality and travel-tech firm OYO respectively for unfair business practices.

Share Market Live

NSE

It was alleged that MMT-Go imposed a price parity in their agreements with hotel partners. Under such pacts, the hotel partners are not allowed to sell their rooms on any other platform or on its own online portal at a price below the price at which it is being offered on the two entities' platforms.

It was also alleged that MMT-Go gave preferential treatment to OYO on its platform, further leading to a denial of market access to other players.

Also Read: Netflix adds over 2 million subscribers since July, shares surge near 14%

The commission directed MMT-Go to modify its agreements with hotels, to remove the price and room availability parity obligations imposed by it with respect to other online travel agents. Also, the commission asked MMT-Go to modify its agreement with hotels to remove the exclusivity conditions.

Further, it directed MMT-Go to provide access to its platform on a fair, transparent and non-discriminatory basis to the hotels by formulating the platforms’ listing terms and conditions in an objective manner and notifying all its hotels about the modifications.

Responding to the CCI order, the OYO spokesperson said, "We have received a copy of the CCI order and are reviewing it in detail. Most OYO customers book directly through our app, website, and other channels in India. We continue to work with all OTAs as distribution partners.

OYO believes that our business practices and conduct comply with all applicable laws and will take all necessary steps to explain our position in the appropriate forums."

First Published:Oct 19, 2022 7:35 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Surrozen Files $200 Million Mixed Shelf
Surrozen Files $200 Million Mixed Shelf
Mar 23, 2026
05:47 PM EDT, 03/23/2026 (MT Newswires) -- Surrozen ( SRZN ) filed a registration statement Monday with the US Securities and Exchange Commission for the potential sale of up to $200 million in securities. The filing covers common and preferred stock, debt securities, and warrants. Net proceeds will be used for working capital and general corporate purposes. ...
Globus Medical Board Member John DeFord Steps Down
Globus Medical Board Member John DeFord Steps Down
Mar 23, 2026
05:46 PM EDT, 03/23/2026 (MT Newswires) -- Globus Medical ( GMED ) said late Monday that John DeFord has resigned from its board, starting immediately. DeFord's decision was not due to any disagreement with the company, according to a filing with the US Securities and Exchange Commission. DeFord will not seek re-election at the annual meeting of stockholders on June...
Outlook Therapeutics Commences Public Offering
Outlook Therapeutics Commences Public Offering
Mar 23, 2026
05:47 PM EDT, 03/23/2026 (MT Newswires) -- Outlook Therapeutics ( OTLK ) said late Monday it has commenced a best-efforts public offering of its common stock, or pre-funded warrants, and accompanying warrants exercisable for its common stock. The offering is subject to conditions, and there can be no assurance about the closing date, actual size or terms of the offering,...
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Mar 23, 2026
-- Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s Inflammation Portfolio -- -- Gilead Intends to Enter into a Strategic Collaboration with Galapagos on the Ouro Portfolio of Medicines -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. ( GILD ) announced today it has entered into a definitive agreement to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved